Cell And Gene Therapy Supply Chain Software Market Estimated to Experience a Hike in Growth by 2035

Cell and gene therapies require highly specialized, end-to-end supply chain orchestration—from patient sample collection and manufacturing to logistics and treatment follow-up. Dedicated software platforms (EMS, LIMS, IMS, cell orchestration platforms, QMS, and others) help manage chain of identity, chain of custody, scheduling, and quality across decentralized and personalized workflows.

Supporting this complex ecosystem is the Cell and Gene Therapy Supply Chain Software Market, valued at USD 312 million in 2025 and projected to reach USD 356 million in 2026 and USD 1,329 million by 2035 at a CAGR of 15.8%. Cloud-based deployment and cell orchestration platforms are among the faster-growing segments. Pharmaceutical companies, cell therapy labs, hospitals, and research institutes are the primary end users.

Asia-Pacific is expected to grow at a higher CAGR. Leading providers include Azenta Life Sciences, Cryoport, Lonza, TraceLink, TrakCel, Veeva Systems, and others. Rising commercial approvals of cell and gene therapies and the need for scalable, compliant digital infrastructure will continue to drive adoption through 2035.
Read More: https://www.rootsanalysis.com/reports/cell-therapies-supply-chain/260.html